Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2006

01-09-2006 | Research Letter

Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients

Authors: K. Svennevig, S. O. Kolset, H.-J. Bangstad

Published in: Diabetologia | Issue 9/2006

Login to get access

Excerpt

To the Editor: Hyperglycaemia is associated with increased inflammatory activity, endothelial dysfunction and microvascular complications in patients with type 1 diabetes mellitus. Low-grade inflammation and changes in functions of different constituents of the capillary wall may contribute to the development of complications. …
Literature
1.
Gotte M, Echtermeyer F (2003) Syndecan-1 as a regulator of chemokine function. Scientific World Journal 3:1327–1331PubMed
2.
Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF (1994) Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37:483–490PubMedCrossRef
3.
Sheetz MJ, King GL (2002) Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579–2588PubMedCrossRef
4.
Creager MA, Luscher TF, Cosentino F, Beckman JA (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 108:1527–1532PubMedCrossRef
5.
Basu S, Larsson A, Vessby J, Vessby B, Berne C (2005) Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care 28:1371–1375PubMedCrossRef
6.
Mulivor AW, Lipowsky HH (2004) Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 286:H1672–H1680PubMedCrossRef
7.
Mulivor AW, Lipowsky HH (2002) Role of glycocalyx in leukocyte–endothelial cell adhesion. Am J Physiol Heart Circ Physiol 283:H1282–H1291PubMed
8.
Yamamoto M, Hara H, Adachi T (2001) Nitric oxide and its decomposed derivatives decrease the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett 505:296–300PubMedCrossRef
9.
Ha TS, Duraisamy S, Faulkner JL, Kasinath BS (2004) Regulation of glomerular endothelial cell proteoglycans by glucose. J Korean Med Sci 19:245–252PubMedCrossRef
Metadata
Title
Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients
Authors
K. Svennevig
S. O. Kolset
H.-J. Bangstad
Publication date
01-09-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0330-4

Other articles of this Issue 9/2006

Diabetologia 9/2006 Go to the issue

Research Letter

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione

Short Communication

Oesophageal dysmotility, delayed gastric emptying and autonomic neuropathy correlate to disturbed glucose homeostasis

Short Communication

Higher incidence of childhood-onset type 1 diabetes mellitus in remote areas: a UK regional small-area analysis

Article

Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer’s disease and decreases it in wild-type mice

Erratum

PGC-1α: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes

Article

The relation between size at birth and risk of type 1 diabetes is not influenced by adjustment for the insulin gene (-23HphI) polymorphism or HLA-DQ genotype
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits